CDB-2914 for Uterine Leiomyomata Treatment: A Randomized Controlled Trial

OBJECTIVE: To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma size and symptoms. METHODS: Premenopausal women with symptomatic uterine leiomyomata were randomly assigned to CDB-2914 at 10 mg (T1) or 20 mg (T2) daily or to placebo (P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Levens, Eric D., Potlog-Nahari, Clariss, Armstrong, Alicia Y., Wesley, Robert, Premkumar, Ahalya, Blithe, Diana L., Blocker, Wendy, Nieman, Lynnette K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2742990/
https://ncbi.nlm.nih.gov/pubmed/18448745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0b013e3181705d0e
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados